The company behind popular weight-loss drugs failed to disclose millions of pounds it paid to healthcare groups and patient organisations, a pharmaceutical watchdog has said.
Payments were also misattributed to the wrong organisations, including £338,435 paid to the World Obesity Federation that was originally listed as paid to the Association for British HealthTech Industries.
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies, according to the Prescription Medicines Code of Practice Authority (PMCPA).
The investigation, led by researchers from the University of Bath, UK and Lund University, Sweden, uncovered a number of serious breaches of the pharmaceutical industry's code of practice.
However, this latest investigation revealed that even after conducting an internal review, the company still failed to record a further £635,000 in additional payments.
